Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
EGFR Positive Non-small Cell Lung Cancer: early-phase trial registry
1 of 2 indexed EGFR Positive Non-small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · 1 currently recruiting · #7,188 of 28,707 conditions by registered trial count
EGFR Positive Non-small Cell Lung Cancer: 2 US clinical trials tracked, 1 recruiting.
EGFR Positive Non-small Cell Lung Cancer is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Black Diamond Therapeutics, running 1 of these trials.
Enrollment posture brief
Registry condition egfr-positive-non-small-cell-lung-cancer
OPEN 1 | RECR 50% | LATE 0 | EARLY 1 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)
EGFR Positive Non-small Cell Lung Cancer lists 1 open slots (50% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for EGFR Positive Non-small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
EGFR Positive Non-small Cell Lung Cancer is recruiting above its size-band peers.
1 of 2 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
2 total, page 1 of 1
Patient-centered, Optimal Integration of Survivorship and Palliative Care
Massachusetts General Hospital
NCT04900935
Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations
Black Diamond Therapeutics
NCT05256290
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on EGFR Positive Non-small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on EGFR Positive Non-small Cell Lung Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this EGFR Positive Non-small Cell Lung Cancer page
2 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 EGFR Positive Non-small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Black Diamond Therapeutics sponsors the most EGFR Positive Non-small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See Black Diamond Therapeutics's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This EGFR Positive Non-small Cell Lung Cancer condition card totals 2 registered trials; most-linked intervention silevertinib (BDTX-1535) monotherapy; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.